|
|
Article: FDA APPROVES PROKINE FOR TREATMENT OF BONE MARROW TRANSPLANT ENGRAFTMENT FAILURE
- Article from:
- PR Newswire
- Article date:
- January 3, 1992
CopyrightCOPYRIGHT 1992 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FDA APPROVES PROKINE FOR TREATMENT OF BONE MARROW
TRANSPLANT ENGRAFTMENT FAILURE
SOMERVILLE, N.J., Jan. 3 /PRNewswire/ -- Sargramostim, a yeast- derived granulocyte-macrophage colony stimulating factor, improves survival of cancer patients in whom myeloid engraftment is delayed or is lost after bone marrow transplantation.
Based on study data submitted to the U.S. Food and Drug Administration, Sargramostim will be permitted to be marketed for myeloid engraftment delay or failure. Sargramostim is manufactured by Immunex Corporation and distributed under the trade name Leukine. It is also distributed by Hoechst-Roussel Pharmaceuticals Inc. under ...